News

New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous...

The Bristol-Myers Squibb Foundation has announced $6 million in additional grants through its Together on Diabetes™ initiative that will help more adults living with type 2 diabetes better manage their disease and make behavioral changes that can improve...

A study led by Karolinska Institutet reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a...

Abbott announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA  in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS). At week 12, nearly...

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center. The results of...

Results from a study published online in Blood, the Journal of the American Society of Hematology (ASH), demonstrate that inclusion of carfilzomib, a novel targeted therapy for multiple myeloma, in combination with lenalidomide and low-dose dexamethasone, resulted in...

Roche announced that the Phase III EMILIA study of trastuzumab emtansine met its co-primary endpoint, of a significant improvement in the time patients with HER2-positive metastatic breast cancer (mBC) lived without their disease getting worse. ...